Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prolyl and lysyl hydroxylases are a group of 2-oxoglutarate-dependent dioxygenases that play essential roles in the post-translational modification of proteins, most notably collagen (Gorres & Raines, 2010). Prolyl hydroxylases (PHDs) catalyze the 4-hydroxylation of proline residues, which is required for the thermal stability of the collagen triple helix, and also act as cellular oxygen sensors by hydroxylating Hypoxia-Inducible Factor (HIF) alpha subunits to trigger their degradation under normoxic conditions (Maxwell & Eckardt, 2016). Lysyl hydroxylases (PLODs) catalyze the hydroxylation of lysine residues in collagen, providing the sites for glycosylation and the formation of stable covalent cross-links that are vital for the structural integrity of the extracellular matrix (Yamauchi & Sricholpech, 2012). Dysregulation of these enzymes is associated with various diseases, including anemia, where HIF-PHD inhibitors are used to stimulate erythropoiesis, and fibrotic disorders or cancer, where excessive collagen modification promotes disease progression (Gilkes et al., 2013). Therapeutic agents targeting these enzymes include approved HIF-PHD inhibitors like Roxadustat and Daprodustat for renal anemia, while inhibitors of collagen-modifying hydroxylases are being explored for anti-fibrotic and anti-cancer therapy.
Inhibition of 2-oxoglutarate-dependent dioxygenase activity by competing with the co-substrate 2-oxoglutarate or chelating the active site ferrous iron (Fe2+), thereby preventing the hydroxylation of specific proline or lysine residues on target proteins such as collagen or HIF-1α (Maxwell & Eckardt, 2016; Gorres & Raines, 2010).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prolyl and lysyl hydroxylases (PHD/PLOD).